ABSTRACT
Background Left ventricular (LV) systolic dysfunction is associated with over 8-fold increased risk of heart failure and a 2-fold risk of premature death. The use of electrocardiogram (ECG) signals in screening for LV systolic dysfunction is limited by their availability to clinicians. We developed a novel deep learning-based approach that can use ECG images for the screening of LV systolic dysfunction.
Methods Using 12-lead ECGs plotted in multiple different formats, and corresponding echocardiographic data recorded within 15 days from the Yale-New Haven Hospital (YNHH) during 2015-2021, we developed a convolutional neural network algorithm to detect LV ejection fraction < 40%. The model was validated within clinical settings at YNHH as well as externally on ECG images from Cedars Sinai Medical Center in Los Angeles, CA, Lake Regional Hospital (LRH) in Osage Beach, MO, Memorial Hermann Southeast Hospital in Houston, TX, and Methodist Cardiology Clinic of San Antonia, TX. In addition, it was validated in the prospective Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Gradient-weighted class activation mapping was used to localize class-discriminating signals in ECG images.
Results Overall, 385,601 ECGs with paired echocardiograms were used for model development. The model demonstrated high discrimination power across various ECG image formats and calibrations in internal validation (area under receiving operation characteristics [AUROC] 0.91, area under precision-recall curve [AUPRC] 0.55), and external sets of ECG images from Cedars Sinai (AUROC 90, AUPRC 0.53), outpatient YNHH clinics (AUROC 0.94, AUPRC 0.77), LRH (AUROC 0.90, AUPRC 0.88), Memorial Hermann Southeast Hospital (AUROC 0.91, AUPRC 0.88), Methodist Cardiology Clinic (AUROC 0.90, AUPRC 0.74), and ELSA-Brasil cohort (AUROC 0.95, AUPRC 0.45). An ECG suggestive of LV systolic dysfunction portended over 27-fold higher odds of LV systolic dysfunction on TTE (OR 27.5, 95% CI, 22.3-33.9 in the held-out set). Class-discriminative patterns localized to the anterior and anteroseptal leads (V2-V3), corresponding to the left ventricle regardless of the ECG layout. A positive ECG screen in individuals with LV ejection fraction ≥ 40% at the time of initial assessment was associated with a 3.9-fold increased risk of developing incident LV systolic dysfunction in the future (HR 3.9, 95% CI 3.3-4.7, median follow-up 3.2 years).
Conclusions We developed and externally validated a deep learning model that identifies LV systolic dysfunction from ECG images. This approach represents an automated and accessible screening strategy for LV systolic dysfunction, particularly in low-resource settings.
What is New?
A convolutional neural network model that accurately identifies LV systolic dysfunction from ECG images across subgroups of age, sex, and race.
The model shows robust performance across multiple institutions and health settings, both applied to ECG image databases as well as directly uploaded single ECG images to a web-based application by clinicians.
The approach provides information for both screening of LV systolic dysfunction and its risk based on ECG images alone.
What are the clinical implications?
Our model represents an automated screening strategy for LV systolic dysfunction on a variety of ECG layouts.
With availability of ECG images in practice, this approach overcomes implementation challenges of deploying an interoperable screening tool for LV systolic dysfunction in resource-limited settings.
This model is available in an online format to facilitate real-time screening for LV systolic dysfunction by clinicians.
Competing Interest Statement
Dr. Mortazavi reported receiving grants from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food and Drug Administration, and the US Department of Defense Advanced Research Projects Agency outside the submitted work; in addition, Dr. Mortazavi has a pending patent on predictive models using electronic health records (US20180315507A1). Antonio H. Ribeiro is funded by Kjell och Marta Beijer Foundation. Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company. Dr Ribeiro is supported in part by CNPq (465518/2014-1, 310790/2021-2 and 409604/2022-4) and by FAPEMIG (PPM-00428-17, RED-00081-16 and PPE-00030-21). Mr. Sangha and Dr. Khera are the coinventors of U.S. Provisional Patent Application No. 63/346,610, "Articles and methods for format independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning". Dr. Khera is also a founder of Evidence2Health, a precision health platform to improve evidence-based care.
Funding Statement
This study was supported by research funding awarded to Dr. Khera by the Yale School of Medicine and grant support from the National Heart, Lung, and Blood Institute of the National Institutes of Health under the award K23HL153775. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed by the Yale Institutional Review Board, which approved the study protocol and waived the need for informed consent as the study represents secondary analysis of existing data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The validation of the models has been expanded to additional datasets.
Data Availability
All data produced in the present work are contained in the manuscript
ABBREVIATIONS AND ACRONYMS
- LV
- Left ventricle
- ECG
- Electrocardiography
- AI
- Artificial Intelligence
- LVEF
- Left ventricular ejection fraction
- YNHH
- Yale New Haven Hospital
- TTE
- Transthoracic echocardiography
- LRH
- Lake Regional Hospital
- ELSA-Brasil
- ELSA-Brasil, Estudo Longitudinal de Saúde do Adulto (The Brazilian Longitudinal Study of Adult Health)
- Grad-CAM
- Gradient-weighted Class Activation Mapping
- AUROC
- Area under receiving operation characteristics
- AUPRC
- Area under precision recall curve
